AGM/EGM3 Aug 2026, 03:13 pm
Jenburkt Pharmaceuticals Submits FY26 Annual Report & AGM Notice
AI Summary
Jenburkt Pharmaceuticals Ltd has submitted its Annual Report for the Financial Year 2025-26. The report includes audited standalone financial statements, the auditors' report, directors' report, and the notice for the 41st Annual General Meeting (AGM). The AGM is scheduled for September 4, 2026, at 3:30 p.m. IST, to be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The report also details the company's commitment to CSR, stemming from its founder's philosophy of giving back to the community, with initiatives dating back to the 1950s. The Annual Report is being disseminated electronically as per regulatory guidelines.
Key Highlights
- FY26 Annual Report submitted, including audited financials.
- 41st AGM scheduled for September 4, 2026, via VC/OAVM.
- Report contains Directors' Report, Auditors' Report, and Corporate Governance.
- Company highlights long-standing CSR philosophy and initiatives.
- Annual Report distributed electronically per SEBI-LODR regulations.
Price Impact
More from JENBURPH